TRIB vs. NYMX, OCX, ICCC, AWH, BMRA, CDIO, MYMD, TKNO, ACHV, and PLUR
Should you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Nymox Pharmaceutical (NYMX), OncoCyte (OCX), ImmuCell (ICCC), Aspira Women's Health (AWH), Biomerica (BMRA), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Pluri (PLUR). These companies are all part of the "medical" sector.
Trinity Biotech vs.
Nymox Pharmaceutical (NASDAQ:NYMX) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
Nymox Pharmaceutical has higher earnings, but lower revenue than Trinity Biotech. Nymox Pharmaceutical is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
0.8% of Nymox Pharmaceutical shares are held by institutional investors. Comparatively, 18.4% of Trinity Biotech shares are held by institutional investors. 54.0% of Nymox Pharmaceutical shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Trinity Biotech received 127 more outperform votes than Nymox Pharmaceutical when rated by MarketBeat users. Likewise, 68.06% of users gave Trinity Biotech an outperform vote while only 51.55% of users gave Nymox Pharmaceutical an outperform vote.
Nymox Pharmaceutical has a net margin of 0.00% compared to Trinity Biotech's net margin of -54.84%. Trinity Biotech's return on equity of -724.07% beat Nymox Pharmaceutical's return on equity.
Nymox Pharmaceutical has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
In the previous week, Trinity Biotech had 3 more articles in the media than Nymox Pharmaceutical. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Nymox Pharmaceutical. Trinity Biotech's average media sentiment score of 0.43 beat Nymox Pharmaceutical's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.
Summary
Trinity Biotech beats Nymox Pharmaceutical on 10 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Trinity Biotech Competitors List
Related Companies and Tools